Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Soluble amyloid-beta oligomers (Aβo) start to accumulate in the human brain one to two decades before any clinical symptoms of Alzheimer's disease (AD) and are implicated in synapse loss, one of the best predictors of memory decline that characterize the illness. Cognitive impairment in AD was traditionally thought to result from a reduction in synaptic activity which ultimately induces neurodegeneration. More recent evidence indicates that in the early stages of AD synaptic failure is, at least partly, induced by neuronal hyperactivity rather than hypoactivity. Here, we review the growing body of evidence supporting the implication of soluble Aβo on the induction of neuronal hyperactivity in AD animal models, in vitro, and in humans. We then discuss the impact of Aβo-induced hyperactivity on memory performance, cell death, epileptiform activity, gamma oscillations, and slow wave activity. We provide an overview of the cellular and molecular mechanisms that are emerging to explain how Aβo induce neuronal hyperactivity. We conclude by providing an outlook on the impact of hyperactivity for the development of disease-modifying interventions at the onset of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Steriade, M., Nunez, A., & Amzica, F. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-08-03252.1993 · Cited by 1,903
Palop, J. J., Chin, J., Roberson, E. D., Wang, J., Thwin, M. T., Bien-Ly, N., Yoo, J., Ho, K. O., Yu, G.-Q., Kreitzer, A., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.07.025 · Cited by 1,653
Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks
Palop, J. J., & Mucke, L. (2010) · Nature Neuroscience · doi:10.1038/nn.2583 · Cited by 1,651
Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders
Hardingham, G. E., & Bading, H. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2911 · Cited by 1,644 · cited 1×
“It was found that Aβo altered LTP and LTD by decreasing neuronal glutamate reuptake, thereby contributing to the diffusion of glutamate outside the post-synaptic density where it can activate extrasynaptic GluN2B-containing NMDA receptors and induced cell death (Li et al., 2009, 2011; Hardingham and Bading, 2010).”
BackgroundDistinct patterns of brain activity in young carriers of the APOE -ε4 allele
Filippini, N., MacIntosh, B. J., Hough, M. G., Goodwin, G. M., Frisoni, G. B., Smith, S. M., Matthews, P. M., Beckmann, C. F., & Mackay, C. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811879106 · Cited by 1,613 · cited 2×
“Higher hippocampal activation was also observed before any clinical symptoms in carriers of the APOE4 allele, the most important genetic risk factor for late-onset sporadic AD (Bookheimer et al., 2000; Trivedi et al., 2008; Filippini et al., 2009; Kunz et al., 2015).”
BackgroundThe synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 1×
“Levetiracetam (Keppra) is an atypical anti-epileptic drug that is assumed to decrease impulse conduction across excitatory synapses by inhibiting pre-synaptic Ca2+ channels, and by acting on the synaptic vesicle protein SV2A (Lynch et al., 2004; Vogl et al., 2012).”
Background
Cited by
Meftah, S., & Gan, J. (2023) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2023.1129036 · Cited by 205
Pathogenesis of sporadic Alzheimer's disease by deficiency of NMDA receptor subunit GluN3A
Zhong, W., Wu, A., Berglund, K., Gu, X., Jiang, M. Q., Talati, J., Zhao, J., Wei, L., & Yu, S. P. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12398 · Cited by 59
Sensory processing deficits and related cortical pathological changes in Alzheimer’s disease
Zhang, N. K., Zhang, S. K., Zhang, L. I., Tao, H. W., & Zhang, G.-W. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1213379 · Cited by 49
“While primary cortices appear to be relatively spared from amyloid plaques and NFT formation, soluble amyloid-beta and tau have been proposed to be able to induce hyperactivity (Kopeikina et al., 2012; Hector and Brouillette, 2021), adding another layer to the complex pathogenesis of AD.”
BackgroundLomoio, S., Pandey, R. S., Rouleau, N., Menicacci, B., Kim, W., Cantley, W. L., Haydon, P. G., Bennett, D. A., Young-Pearse, T. L., Carter, G. W., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02147-3 · Cited by 25
“Remarkably, neuronal hyperexcitability has been described in FAD and late-onset AD (LOAD) patients at the early stage of the disease [10].”
The role of microRNA-485 in neurodegenerative diseases
Ryu, I. S., Kim, D. H., Cho, H.-J., & Ryu, J.-H. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0039 · Cited by 25
Metadata
- Authors
- Hector, A., & Brouillette, J.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2021-01-07
- Volume
- 13
- Pages
- 600084-600084
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W3119759716
- Cited by
- 87
- References
- 52
- FWCI
- 6.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease. https://app.cochat.ai/papers/10.3389/fnmol.2020.600084
- The paper
- Hector, A., & Brouillette, J. (2021). Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease. Frontiers in Molecular Neuroscience. https://doi.org/10.3389/fnmol.2020.600084
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.